Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MP-376 in stable cystic fibrosis
NCT00677365Phase 2Completed
- Sponsor
- Amgen
- Start
- Jun 2008
- Primary completion
- Jun 2009
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of levofloxacin inhalation solution in cystic fibrosis (CF) (4 arms), sponsored by Amgen. Primary endpoint: Change in P. Aeruginosa Density at 28 days. Started Jun 2008; status: completed.
02
Drugs
levofloxacin inhalation solution
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT00677365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00677365.